Glucagon-like Peptide-1 Receptor Agonists: Are They as Good as They Seem? A Systematic Review of Severe Adverse Effects

As obesity evolves as a global pandemic, the use of drugs to treat it is booming. The latest among these are Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Along with their use, the incidence of adverse events has become more common. Although severe effects have been mentioned, details and a...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Endocrines
المؤلفون الرئيسيون: Pranjal Sharma, Venkata Buddhavarapu, Gagandeep Dhillon, Ram Kishun Verma, Ramprakash Devadoss, James Raynor, Ripudaman Munjal, Harpreet Grewal, Rahul Kashyap
التنسيق: مقال
اللغة:الإنجليزية
منشور في: MDPI AG 2024-08-01
الموضوعات:
GLP-1 agonist
glucagon-like peptide-1 receptor agonist
semaglutide
liraglutide
dulaglutide
side effects
الوصول للمادة أونلاين:https://www.mdpi.com/2673-396X/5/3/23

الانترنت

https://www.mdpi.com/2673-396X/5/3/23

مواد مشابهة